The DOI matches its Crossref record.
Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure
Abstract
OBJECTIVE: Levosimendan is a new calcium sensitizer with additional vasodilatory properties developed for the short-term intravenous treatment of congestive heart failure. The aims of the present study were to determine the pharmacokinetics and hemodynamic effects of levosimendan and its metabolites during and after a 24-hour levosimendan infusion. METHODS: The study was an open-label, non-randomized, phase II study in 2 centers. Twelve patients with NYHA III-IV heart failure received 0.2 microg/kg/min continuous infusion of levosimendan for 24 hours. Blood samples for the determination of plasma concentrations of the parent drug and the metabolites were drawn repeatedly during the infusion and the 2-week follow-up period. Heart rate from Holter recordings and blood pressure were measured. RESULTS: The elimination half-life of levosimendan was 1.3 hours and that of the metabolites 75-78 hours. The mean maximum increase in heart rate of 10 bpm (p < 0.005) and the mean maximum decreases in systolic and diastolic blood pressure of 12 mmHg and 8 mmHg (p < 0.05 for both), respectively, were observed during the first day after stopping levosimendan infusion. The hemodynamic effects slowly declined during the follow-up, and after 1 week no statistically significant differences compared with baseline were observed. No increase in ventricular arrhythmias was seen. CONCLUSION: A 24-hour infusion of levosimendan induces hemodynamic effects lasting several days after stopping the infusion. The prolongation of the effects beyond the infusion period is most likely due to an active metabolite with a long half-life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mebazaa, A., Nieminen, M. S., Packer, M., Cohen-Solal, A., Kleber, F. X., Pocock, S. J., Thakkar, R., Padley, R. J., Põder, P., Kivikko, M., et al. (2007) · JAMA · doi:10.1001/jama.297.17.1883 · Cited by 994
Self-citationPacker, M., Colucci, W., Fisher, L., Massie, B. M., Teerlink, J. R., Young, J., Padley, R. J., Thakkar, R., Delgado-Herrera, L., Salon, J., et al. (2013) · JACC: Heart Failure · doi:10.1016/j.jchf.2012.12.004 · Cited by 436
Price, L. C., Wort, S. J., Finney, S. J., Marino, P. S., & Brett, S. J. (2010) · Critical Care · doi:10.1186/cc9264 · Cited by 389
Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis
Gordon, A. C., Perkins, G. D., Singer, M., McAuley, D. F., Orme, R. M. L., Santhakumaran, S., Mason, A. J., Cross, M., Al-Beidh, F., Best-Lane, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609409 · Cited by 372
Levosimendan: Molecular mechanisms and clinical implications
Papp, Z., Édes, I., Fruhwald, S., De Hert, S. G., Salmenperä, M., Leppikangas, H., Mebazaa, A., Landoni, G., Grossini, E., Caimmi, P., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.07.022 · Cited by 319
Self-citation
Metadata
- Authors
- Kivikko, M., Antila, S., Eha, J., Lehtonen, L., & Pentikäinen, P. J.
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2002-10-01
- Volume
- 40
- Issue
- 10
- Pages
- 465-471
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W2032520387
- Cited by
- 195
- References
- 0
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. https://app.cochat.ai/papers/10.5414/cpp40465
- The paper
- Kivikko, M., Antila, S., Eha, J., Lehtonen, L., & Pentikäinen, P. J. (2002). Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cpp40465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.